High impact
OTC drug exclusion reminder and SGLT2 inhibitor update
Harvard Pilgrim Health Care·Effective Oct 1, 2026
Point32Health is implementing two major pharmacy coverage changes: (1) Effective Oct 1, 2026, excluding coverage for OTC drugs and prescription equivalents (antihistamines, H2 blockers, nasal steroids, fluoride, PPIs) except pediatric formulations and ACA-mandated drugs; (2) Effective Nov 15, 2026, moving all brand-name SGLT2 inhibitors to non-formulary status for Commercial large group plans, with automatic generic substitution for Farxiga and Xigduo XR, and prior authorization required for members on other brand names.